This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Dec 2011

Synta Announces Publication of Ganetespib Results in Molecular Cancer Therapeutics

Synta has announced the publication in Molecular Cancer Therapeutics of ganetespib results.

US biopharmaceutical firm Synta Pharmaceuticals announced yesterday the publication in Molecular Cancer Therapeutics of ganetespib results including pharmacologic and biological properties that distinguish ganetespib from other Hsp90 inhibitors.


The first generation of Hsp90 inhibitors were derived from the natural product geldanamycin, originally identified as an antibiotic. These include 17-AAG and derivatives or analogs with improved solubility such as 17-DMAG and IPI-504.


Development of these early Hsp90 inhibitors, however, has been hampered by several drawbacks, including the hepatotoxicity associated with chemical properties of this ansamycin family of compounds. In an effort to overcome these limitations, next-generation synthetic Hsp90 inhibito

Related News